Determining the optimal dose of haloperidol in first-episode psychosis
Abstract
Uncertainty exists as to the most appropriate dose of haloperidol in first-episode psychosis. This study set out to determine whether ultra-low doses of haloperidol could successfully treat patients with first-episode psychosis. Thirty-five patients with a first episode of psychosis were treated with haloperidol in an open label, fixed protocol over a 12-week period with doses restricted to 1 mg per day for the first 4 weeks. Twenty-nine (83%) remained on haloperidol after 12 weeks at a mean dose of 1.78 mg per day, 16 (55%) had stabilized on 1 mg/day or less. The mean percentage reduction in Positive and Negative Symptom Scale score between baseline and 6 and 12 weeks was 30.3% (SD 20.9%) and 41.4% (SD 16.6%), respectively. There were no significant differences in mean extrapyramidal symptom ratings between baseline and 12 weeks. Ultra-low doses of haloperidol are effective and well tolerated in first-episode psychosis. Initial doses should be maintained for a sufficient period of time to allow for the medication to take full effect.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In another study, 1 mg of haloperidol or less was effective in symptom reduction in first-episode psychosis in the majority of patients.
“in another study, 1 mg of haloperidol or less was effective in symptom reduction in FEP in the majority of patients.98”
From A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse (2021) · cites this paper as [98]
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369 · see citing works
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,841 · see citing works
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378 · see citing works
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
Simpson, G. M., B., M., B., G., Angus, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,265 · see citing works
A Rating Scale for Drug-Induced Akathisia
Barnes, T. R. E. (1989) · The British Journal of Psychiatry · doi:10.1192/bjp.154.5.672 · Cited by 2,179 · see citing works
Farde, L. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820070032005 · Cited by 1,420 · see citing works
Kapur, S., Zipursky, R., Jones, C., Remington, G., & Houle, S. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.4.514 · Cited by 1,090 · see citing works
Leucht, S., Pitschel‐Walz, G., Abraham, D., & Kissling, W. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00105-4 · Cited by 795 · see citing works
Significance of Neuroleptic Dose and Plasma Level in the Pharmacological Treatment of Psychoses
Baldessarini, R. J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800250095013 · Cited by 545 · see citing works
Meltzer, H. Y., & Okayli, G. (1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.2.183 · Cited by 436 · see citing works
Optimal Dose of Neuroleptic in Acute Schizophrenia
McEvoy, J. P. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810320063009 · Cited by 384 · see citing works
Tollefson, G. D., & Sanger, T. M. (1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.4.466 · Cited by 306 · see citing works
ZIMBROFF, D. L., Kane, J. M., Tamminga, C. A., Daniel, D. G., Mack, R. J., Wozniak, P. J., Sebree, T. B., Wallin, B., & Kashkin, K. B. (1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.6.782 · Cited by 306 · see citing works
Low-Dose Neuroleptic Treatment of Outpatient Schizophrenics
Kane, J. M. (1983) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.01790070083010 · Cited by 272 · see citing works
Depressive Signs and Symptoms in Schizophrenia
Tollefson, G. D., Sanger, T. M., Lu, Y., & Thieme, M. E. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.3.250 · Cited by 259 · see citing works
Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia
Wolkin, A., Barouche, F., Wolf, A. P., Rotrosen, J., Fowler, J. S. L., Shiue, C., Cooper, T. B., & Brodie, J. D. (1989) · American Journal of Psychiatry · doi:10.1176/ajp.146.7.905 · Cited by 258 · see citing works
High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study
Kapur, S., Remington, G. J., Jones, C. E., Wilson, A., DaSilva, J. N., Houle, S., & Zipursky, R. B. (1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.7.948 · Cited by 251 · see citing works
Beasley, C. M., Dellva, M. A., Tamura, R., Morgenstern, H., Glazer, W. M., Ferguson, K., & Tollefson, G. D. (1999) · The British Journal of Psychiatry · doi:10.1192/bjp.174.1.23 · Cited by 241 · see citing works
Low- and conventional-dose maintenance therapy with fluphenazine decanoate. Two-year outcome.
Marder, S. R., van Putten, T., Mintz, J., Lebell, M., Mckenzie, J., & May, P. R. A. (1987) · Archives of General Psychiatry · doi:10.1001/archpsyc.1987.01800180028005 · Cited by 226 · see citing works
Lieberman, J. A., Koreen, A., Chakos, M., Sheitman, B., Woerner, M. G., Alvir, J. M. J., & Bilder, R. M. (1996) · PubMed · Cited by 211 · see citing works
Effects of clozapine on cognitive function in schizophrenia.
Lee, M. A., Thompson, P. A., & Meltzer, H. Y. (1994) · PubMed · Cited by 199 · see citing works
The Recognition and Management of Early Psychosis: A Preventive Approach
Jackson, H. J., & McGorry, P. D. (2009) · Medical Entomology and Zoology · Cited by 190 · see citing works
A Controlled Dose Comparison of Haloperidol in Newly Admitted Schizophrenic Patients
Putten, T. V. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810200062009 · Cited by 188 · see citing works
Risperidone in the Treatment of First-Episode Psychotic Patients: A Double-Blind Multicenter Study
Emsley, R. A., & Risperidone Working Group (1999) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033413 · Cited by 183 · see citing works
The Concept of Recovery and Secondary Prevention in Psychotic Disorders
McGorry, P. D. (1992) · Australian & New Zealand Journal of Psychiatry · doi:10.3109/00048679209068305 · Cited by 173 · see citing works
A Prospective, Multicenter Study of Patients' Refusal of Antipsychotic Medication
Hoge, S. K. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810220065008 · Cited by 162 · see citing works
Course of treatment response in first-episode and chronic schizophrenia
Szymanski, S., Cannon, T. D., Gallacher, F., Erwin, R. J., & Gur, R. E. (1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.4.519 · Cited by 154 · see citing works
The Recognition and Management of Early Psychosis: A Preventive Approach
Gers, S. (2000) · Psychiatric Services · doi:10.1176/appi.ps.51.6.823 · Cited by 141 · see citing works
Kelley, M. E., van Kammen, D. P., & Allen, D. N. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.3.406 · Cited by 118 · see citing works
Johnson, D. A. W., Ludlow, J. M., Street, K., & Taylor, R. D. W. (1987) · The British Journal of Psychiatry · doi:10.1192/bjp.151.5.634 · Cited by 108 · see citing works
The deficit state in first-episode schizophrenia
Mayerhoff, D. I., Loebel, A. D., Alvir, J., Szymanski, S., Geisler, S. H., Borenstein, M., & Lieberman, J. A. (1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.10.1417 · Cited by 100 · see citing works
D2 and 5-HT2 receptor effects of antipsychotics: bridging basic and clinical findings using PET.
Remington, G., & Kapur, S. (1999) · PubMed · Cited by 90 · see citing works
The Recognition and Management of Early Psychosis
McCreadie, R. G. (2000) · Journal of Forensic Psychiatry · doi:10.1080/09585180050142679 · Cited by 68 · see citing works
Predictors of response to clozapine.
Lieberman, J. A., Kane, J. M., Safferman, A. Z., Pollack, S. Z., Howard, A., Szymanski, S., Masiar, S. J., Kronig, M. H., Cooper, T. B., & NOVACENKO, H. (1994) · PubMed · Cited by 61 · see citing works
Thomas, C. S., & Lewis, S. W. (1998) · The British Journal of Psychiatry · doi:10.1192/bjp.172.2.106 · Cited by 48 · see citing works
Haloperidol Plasma Levels and Dose Optimization
Coryell, W. H., Miller, D. D., & Perry, P. J. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.1.48 · Cited by 48 · see citing works
The annual meeting of the American psychiatric association
(1934) · Psychiatric Quarterly · doi:10.1007/bf01568998 · Cited by 47 · see citing works
Optimal Haloperidol Dosage in First-Episode Psychosis
Zhang-Wong, J., Zipursky, R. B., Beiser, M., & Bean, G. (1999) · The Canadian Journal of Psychiatry · doi:10.1177/070674379904400207 · Cited by 44 · see citing works
Treatment of schizophrenia in low-income countries
Emsley, R. A., Oosthuizen, P. P., Joubert, A. F., Hawkridge, S. M., & Stein, D. J. (1999) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145799001613 · Cited by 24 · see citing works
Olanzapine versus haloperidol in the treatment of first episode psychosis
Sanger, T. M., Lieberman, J. A., Tohen, M. F., & Tollefson, G. D. (1998) · Schizophrenia Research · doi:10.1016/s0920-9964(97)88685-9 · Cited by 22 · see citing works
What is the lowest effective dose of haloperidol? Evidence from pet studies
Kapur, S., Remington, G. J., Jones, C. E., Roy, P., Reed, K., Houle, S., & Zipursky, R. B. (1996) · Biological Psychiatry · doi:10.1016/0006-3223(96)83998-9 · Cited by 5 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements
Buchanan, R. W., Kreyenbuhl, J. A., Kelly, D. L., Noel, J. M., Boggs, D. L., Fischer, B. A., Himelhoch, S. S., Fang, B., Peterson, E. L., Aquino, P. R., et al. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp116 · Cited by 901 · see citing works
“comparing haloperidol 2 mg/day to haloperidol 8 mg/ day in first-episode psychosis, Oosthuizen and colleagues reported no between-group differences in overall psychopathology score and clinician global impression improvement scores, whereas the 2-mg/ day group showed significantly lower parkinsonism adverse effect sco…”
BackgroundThe Schizophrenia Patient Outcomes Research Team (PORT): Updated Treatment Recommendations 2003
Lehman, A. F., Kreyenbuhl, J. A., Buchanan, R. W., Dickerson, F., Dixon, L. B., Goldberg, R., Green-Paden, L. D., Tenhula, W. N., Boerescu, D. A., Tek, C., et al. (2004) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a007071 · Cited by 758 · see citing works
Hasan, A., Falkai, P., Wobrock, T., Lieberman, J. A., Glenthoj, B. Y., Gattaz, W. F., Thibaut, F., Möller, H., & the Wfsbp Task Force on Treatment Guidelines for Schizophrenia (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.696143 · Cited by 637 · see citing works
“…schizophrenia patients in randomized and open trials and such doses were not inferior to higher doses of haloperidol (Kahn et al. 2008; Keefe et al. 2004, 2006; Lieberman et al. 2003b; Moller et al. 2008; Oosthuizen et al. 2004; Oosthuizen et al. 2001; Remington et al. 1998; Schooler et al. 2005).”
The Schizophrenia Patient Outcomes Research Team (PORT): Updated Treatment Recommendations 2009
Kreyenbuhl, J., Buchanan, R. W., Dickerson, F. B., & Dixon, L. B. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp130 · Cited by 499 · see citing works
Falkai, P., Wobrock, T., Lieberman, J. A., Glenthoj, B. Y., Gattaz, W. F., Möller, H., & WFSBP Task Force on Treatment Guide (2006) · The World Journal of Biological Psychiatry · doi:10.1080/15622970500483177 · Cited by 329 · see citing works
Falkai, P., Wobrock, T., Lieberman, J. A., Glenthoj, B. Y., Gattaz, W. F., Möller, H., & WFSBP Task Force on Treatment Guide (2005) · The World Journal of Biological Psychiatry · doi:10.1080/15622970510030090 · Cited by 268 · see citing works
“More recent open (Oosthuizen et al. 2001) and randomised, controlled (Oosthuizen et al. 2004) studies showed low doses of haloperidol (2 mg/day or less) to be at least as effective and better tolerated (lower EPS) than higher doses of haloperidol.”
BackgroundMethodA Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse
Horowitz, M. A., Jauhar, S., Natesan, S., Murray, R. M., & Taylor, D. (2021) · Schizophrenia Bulletin · doi:10.1093/schbul/sbab017 · Cited by 157 · see citing works
Kelly, D. L., Conley, R. R., & Carpenter, W. T. (2005) · Drugs · doi:10.2165/00003495-200565080-00006 · Cited by 86 · see citing works
The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements
Buchanan, R. W., Kreyenbuhl, J. A., Kelly, D. L., Noel, J. M., Boggs, D. L., Fischer, B. A., Himelhoch, S. S., Fang, B., Peterson, E., Aquino, P. R., et al. (2012) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.10.2.194 · Cited by 84 · see citing works
Oosthuizen, P. P., Emsley, R. A., Turner, H. J., & Keyter, N. (2004) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145704004262 · Cited by 67 · see citing works
Emsley, R. A., Turner, H. J., Oosthuizen, P. P., & Carr, J. A. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.06.014 · Cited by 66 · see citing works
“Subjects were treated with very low doses of haloperidol in an open label design according to a fixed protocol which has been fully described elsewhere (Oosthuizen et al., 2001).”
MethodOosthuizen, P., Emsley, R. A., Keyter, N., Niehaus, D. J. H., & Koen, L. (2004) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2004.00448.x · Cited by 64 · see citing works
“Subjects were treated with very low doses of haloperidol in an open label design according to a fixed protocol which has been described fully (36).”
MethodEdinger, M., Bar‐Shalom, D., Rantanen, J., & Genina, N. (2017) · Pharmaceutical Research · doi:10.1007/s11095-017-2126-2 · Cited by 60 · see citing works
“5-4 mg for first-episode psychosis (37).”
BackgroundDrug Utilization Study of Psychotropic Drugs in Outdoor Patients in a Teaching Hospital
Piparva, K. G., Parmar, D., Singh, A. P., Gajera, M. V., & Trivedi, H. R. (2011) · Indian Journal of Psychological Medicine · doi:10.4103/0253-7176.85396 · Cited by 50 · see citing works
“Typical antipsychotic drugs still play an important role in schizophrenia and offer a valid alternative to atypical where atypical drugs are poorly tolerated or where typical are preferred by patients themselves.[11] Guidelines of National Institute of Clinical Excellence (NICE) of 2009 suggest that there is no longer…”
BackgroundMoncrieff, J., Lewis, G., Freemantle, N., Johnson, S., Barnes, T. R. E., Morant, N. J., Pinfold, V., Hunter, R. M., Kent, L., Smith, R., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-030912 · Cited by 50 · see citing works
“8 9 Criticism of randomised controlled trials includes the fact that most focus on relapse and neglect other outcomes.”
Pharmacotherapy of first-episode psychosis
Lambert, M., Conus, P., Lambert, T. J. R., & McGorry, P. D. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.5.717 · Cited by 43 · see citing works
Saikia, A. K., Indukuri, K., & Das, J. (2014) · Organic & Biomolecular Chemistry · doi:10.1039/c4ob01130a · Cited by 38 · see citing works
The relationships between depression and remission in first-episode psychosis.
Oosthuizen, P. P., Emsley, R. A., Niehaus, D. J. H., Koen, L., & Chiliza, B. (2006) · PubMed · Cited by 38 · see citing works
Edinger, M., Iftimi, L.-D., Markl, D., Al‐Sharabi, M., Bar‐Shalom, D., Rantanen, J., & Genina, N. (2019) · AAPS PharmSciTech · doi:10.1208/s12249-019-1423-y · Cited by 36 · see citing works
Amoxapine as an Atypical Antipsychotic: A Comparative Study Vs Risperidone
Apiquián, R., Fresán, A., Ulloa, R. E., de la Fuente‐Sandoval, C., Herrera-Estrella, M., Vazquez, A., Nicolini, H., & Kapur, S. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300796 · Cited by 34 · see citing works
“This has led to search for pharmacological alternatives like the minimum effective doses of conventional antipsychotic drugs (Emsley et al, 1999; McEvoy et al, 1991; Oosthuizen et al, 2001) or the study of older and off-patent drugs for possible atypical antipsychotic efficacy.”
BackgroundA Guide to the Extrapyramidal Side-Effects of Antipsychotic Drugs
Owens, D. G. C. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781139149112 · Cited by 32 · see citing works
The development of antipsychotic drugs
Owens, D. G. C., & Johnstone, E. C. (2018) · Brain and Neuroscience Advances · doi:10.1177/2398212818817498 · Cited by 29 · see citing works
“Pharmacokinetically derived minimum effective doses of new drugs were evaluated against ‘common practice’ doses of haloperidol that in reality were four to five times those established from clinical (Oosthuizen et al., 2001; Rosebush and Mazurek, 1999; Rosenheck et al., 2003) and imaging data (Kapur et al.”
BackgroundChiliza, B., Ojagbemi, A., Esan, O., Asmal, L., Oosthuizen, P. P., Kidd, M., Gureje, O., & Emsley, R. A. (2014) · Early Intervention in Psychiatry · doi:10.1111/eip.12141 · Cited by 28 · see citing works
“The low-dosing strategy comprised initiating antipsychotic treatment at the lowest possible dose, treating initial agitation with a benzodiazepine rather than increasing the antipsychotic dose, and gradual upward titration of antipsychotic dose as necessary until optimal response was obtained.(41)”
BackgroundCrespo‐Facorro, B., Pelayo‐Terán, J. M., & Son, J. M.-V. (2016) · Neurology and Therapy · doi:10.1007/s40120-016-0050-8 · Cited by 25 · see citing works
“Minimum effective doses of 2 mg of haloperidol [121] or lower and 2 mg of risperidone [120] have been previously reported in FEP.”
BackgroundEvidence-based pharmacotherapy of schizophrenia
Emsley, R. A., & Oosthuizen, P. P. (2004) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145704004171 · Cited by 25 · see citing works
Survey on schizophrenia treatment in Mexico: perception and antipsychotic prescription patterns
Apiquián, R., Fresán, A., de la Fuente‐Sandoval, C., Ulloa, R. E., & Nicolini, H. (2004) · BMC Psychiatry · doi:10.1186/1471-244x-4-12 · Cited by 25 · see citing works
“Many studies on the effectiveness of this approach have been published [31-36].”
BackgroundApiquián, R., Fresán, A., Herrera, K., Ulloa, R. E., Lóyzaga, C., de la Fuente‐Sandoval, C., Gutiérrez, D., & Nicolini, H. (2003) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145703003742 · Cited by 24 · see citing works
“Our results support previous reports about the efficacy of minimum doses of haloperidol (McEvoy et al., 1991; Oosthuizen et al., 2001), since patients on this scheme showed a similar improvement in positive, negative and depressive symptoms during the 6-month follow-up compared to patients treated with atypical antips…”
ResultFalkai, P., Wobrock, T., Lieberman, J. A., Glenthoj, B. Y., Gattaz, W. F., & Möller, H. (2006) · Archives of Clinical Psychiatry (São Paulo) · doi:10.1590/s0101-60832006000700003 · Cited by 23 · see citing works
Owens, D. G. C. (2007) · Advances in Psychiatric Treatment · doi:10.1192/apt.bp.107.003970 · Cited by 19 · see citing works
“A major problem is the bradykinesia of druginduced parkinsonism, which in both its objective and subjective characteristics can be difficult, if not impossible, to distinguish from primary negative schizophrenic states (Owens, 1999) (Table 4). Any drug claiming efficacy in negative states cannot produce change simply…”
BackgroundThe Antipsychotic Medication Management Fidelity Scale: Psychometric properties
Ruud, T., Drivenes, K., Drake, R. E., Haaland, V. Ø., Landers, M., Stensrud, B., Heiervang, K. S., Tanum, L., & Bond, G. R. (2020) · Administration and Policy in Mental Health and Mental Health Services Research · doi:10.1007/s10488-020-01018-1 · Cited by 14 · see citing works
Owens, D. G. C. (2012) · Advances in Psychiatric Treatment · doi:10.1192/apt.bp.111.008920 · Cited by 14 · see citing works
Dopamine Receptors and the Treatment of Schizophrenia
Ginovart, N., & Kapur, S. (2010) · The Receptors · doi:10.1007/978-1-60327-333-6_16 · Cited by 8 · see citing works
Antipsychotic Medication in Sub-Saharan Africa
Kumar, S., Sudhakar, S. M., Sajatovic, M., & Levin, J. B. (2020) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001282 · Cited by 11 · see citing works
“6%), respectively.(22) In a prospective cohort study by Ezeme et al,(12) of 172 schizophrenia patients © 2020 Wolters Kluwer Health, Inc.”
BackgroundFirst-episode psychosis: An update
Chiliza, B., Oosthuizen, P. P., & Emsley, R. A. (2008) · South African Journal of Psychiatry · doi:10.4102/sajpsychiatry.v14i1.83 · Cited by 6 · see citing works
Treatment and management of schizophrenia
Owens, D. G. C., & Johnstone, E. C. (2012) · doi:10.1093/med/9780199696758.003.0079 · Cited by 5 · see citing works
Owens, D. G. C. (2010) · Elsevier eBooks · doi:10.1016/b978-0-7020-3137-3.00011-5 · Cited by 5 · see citing works
Goyal, D. V., Munjal, S., & Gupta, D. R. (2016) · IOSR Journal of Dental and Medical Sciences · doi:10.9790/0853-150778087 · Cited by 4 · see citing works
Do we need to change our treatment approach to schizophrenia during the COVID‐19 pandemic?
Ekinci, O., & Ekinci, A. E. (2021) · International Journal of Clinical Practice · doi:10.1111/ijcp.14013 · Cited by 3 · see citing works
Current approaches to the management of schizophrenia
Behan, C. L. (2009) · Irish Journal of Psychological Medicine · doi:10.1017/s0790966700000586 · Cited by 2 · see citing works
Initial assessment and initial pharmacological treatment in theacute phase
Lambert, M. (2009) · Cambridge University Press eBooks · doi:10.1017/cbo9780511576287.012 · Cited by 1 · see citing works
The relationships between antipsychotic dose and efficacy, and the time to treatment response
Emsley, R. A. (2007) · Psychiatrie und Psychotherapie · doi:10.1007/s11326-007-0039-0
Prescribing habits in the pharmacotherapy of schizophrenia
King, R. W. (2011) · University of the Witwatersrand, Johannesburg Institutional Repository on DSpace (University of the Witwatersrand, Johannesburg)
(2005) · CRC Press eBooks · doi:10.1201/b14455-3
(2009) · CRC Press eBooks · doi:10.3109/9780203092835-3
(2002) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.359
Siembida, J., Mohammed, S., Chishty, M., & Leontieva, L. (2022) · Cureus · doi:10.7759/cureus.23744
“There is evidence of even ultra-low doses (1 mg) being beneficial in first break psychosis [47].”
BackgroundMoncrieff, J., Long, M., Priebe, S., Akther-Robertson, J., Barnes, T. R. E., Bray, G., Cooper, R. E., Crellin, N. E., Darton, K., Freemantle, N., et al. (2025) · Programme Grants for Applied Research · doi:10.3310/gjjm0506
- Authors
- Oosthuizen, P., Emsley, R. A., Turner, J., & Keyter, N.
- Affiliations
- Stellenbosch University (ZA)
- Corresponding author
- Oosthuizen, Piet
- ORCID
- Emsley, Robin A.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2001-07
- Volume
- 15
- Issue
- 4
- Pages
- 251-255
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2028922392
- Cited by
- 48
- References
- 41
- Citations by year
- 2025: 1 · 2022: 1 · 2021: 2 · 2020: 2 · 2019: 2 · 2018: 1 · 2017: 1 · 2016: 2 · 2014: 3 · 2012: 4
- FWCI
- 1.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- SUNScholar (Stellenbosch University) (submittedVersion)
- Funders
- Medical Research Council
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
- Keywords
- haloperidol, first-episode psychosis, extrapyramidal symptoms, treatment tolerability
- MeSH terms
- Adolescent, Adult, Basal Ganglia Diseases, Female, Haloperidol, Humans, Male, Middle Aged, Psychiatric Status Rating Scales, Psychotic Disorders, Schizophrenia, Schizophrenic Psychology, Antipsychotic Agents, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
